Latest

Exclusive Rachel Cohrs Zhang

STAT Plus: PhRMA dues fell almost $100 million as major drugmakers exited

Health Care Inc. Newsletter Bob Herman

STAT Plus: A tough year for health insurance stocks as patients get more care

The Readout Meghana Keshavan

STAT Plus: Vertex drug for cystic fibrosis wins approval

A STAT Investigation Casey Ross, Bob Herman, Tara Bannow, and Lizzy Lawrence

STAT Plus: Health Care’s Colossus: Lawmakers call for curbs on UnitedHealth’s growing empire

Health Theresa Gaffney

Gender-affirming surgery disappeared from the U.S. for decades. Now the field is fighting to keep its gains

Health Isabella Cueto

‘We just dismiss people like RFK Jr.’: Infectious disease expert on how — and how not — to rebuild trust

Health tech Brittany Trang

STAT Plus: As Congress waffles on AI, state legislatures step up to fill the void

First Opinion Milena M. Weinstein and Samantha J. Pulliam

The recommended women’s health screening that rarely happens

Health tech Lizzy Lawrence

STAT Plus: FDA designates Neuralink brain implant, infectious disease tests as ‘breakthroughs’

First Opinion Torie Bosch

In defense of state physician health programs’ work with medical students

Politics Rachel Cohrs Zhang

STAT Plus: Congress passes slimmed-down spending bill to keep government open

Biotech Elaine Chen

STAT Plus: Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S.

Politics John Wilkerson, Sarah Owermohle, and Rachel Cohrs Zhang

STAT Plus: Republicans dropped measures to help kids with cancer from the spending bill. Democrats pounced.

Exclusive Tara Bannow

STAT Plus: New York health insurer, executive agree to up to $100 million settlement over Medicare fraud tied to improper diagnoses

Pharma Elaine Chen

STAT Plus: What Novo Nordisk’s disappointing trial results mean for the obesity drug market

Pharma Elaine Chen

STAT Plus: Next-gen obesity treatment from Novo Nordisk misses mark in pivotal trial

Don't Miss Alissa Ambrose and Crystal Milner

STAT’s most memorable photos of 2024

First Opinion Rafael Escandon and Arthur L. Caplan

STAT Plus: Gene therapy trials should emphasize transparency, not secrecy

Health Annalisa Merelli

Maternal mortality data is murky — but the crisis faced by new moms is clear

Health Megan Molteni

Rapid spread of H5N1 bird flu through California dairy herds suggests unknown paths of transmission

Biotech Jonathan Wosen

STAT Plus: Ionis wins FDA approval for a rare disease therapy that lowers triglycerides

Pharmalot Ed Silverman

STAT Plus: Gilead plans to halt free access to an HIV drug, worrying patient advocates

Health tech Timmy Broderick

STAT Plus: FDA OKs novel device for non-invasive treatment of spinal cord injuries

Business Rachel Cohrs Zhang

STAT Plus: House Republicans abandon PBM reform in push to keep government open

The Readout LOUD Allison DeAngelis, Elaine Chen, and Adam Feuerstein

A deep dive on Makary, Vertex’s pain data, & 2025 predictions

Business Lizzy Lawrence and Elizabeth Cooney

STAT Plus: FDA updates rules for which foods are ‘healthy,’ adding salmon and nuts and cutting sugary cereals

Pharma Elaine Chen, Katie Palmer, Ed Silverman, and Lizzy Lawrence

STAT Plus: FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period

Pharmalot Ed Silverman

STAT Plus: Feds accuse CVS of filling ‘thousands’ of illicit opioid prescriptions

Pharmalot Ed Silverman

STAT Plus: Health plan formularies lowered barriers to fair access to some drugs, analysis finds